1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.jaapos.2016.07.229" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.jaapos.2016.07.229</a>
Pages
537–539
Issue
6
Volume
20
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Postmortem vitreous bevacizumab levels of an infant treated for retinopathy of prematurity.
Publisher
An entity responsible for making the resource available
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
2016-12
Subject
The topic of the resource
*Retinopathy of Prematurity; Angiogenesis Inhibitors; Antibodies; Bevacizumab/*analysis; Gestational Age; Humanized; Humans; Infant; Intravitreal Injections; Monoclonal; Newborn; Vascular Endothelial Growth Factor A; Vitreous Body/*chemistry
Creator
An entity primarily responsible for making the resource
Hypes Stephen; Nasser Orwa; Hanna Nancy; Lawhon William; Bouhenni Rachida; Hertle Richard W
Description
An account of the resource
We report the vitreous concentration of bevacizumab after injection for the treatment of retinopathy of prematurity (ROP). A premature neonate diagnosed with type 1 ROP was treated in both eyes with 0.625 mg intravitreal bevacizumab injection at 32 weeks' postconceptual age. Eleven weeks later there was complete regression clinically, but the patient died. Vitreous samples taken at autopsy revealed a bevacizumab vitreous concentration of 41.57 ng/ml. Histopathology of the retina showed residual preretinal neovascularization. Bevacizumab elimination from the infant vitreous is similar to that of adults, and, although complete regression was clinically apparent, it was not confirmed histopathologically.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.jaapos.2016.07.229" target="_blank" rel="noreferrer noopener">10.1016/j.jaapos.2016.07.229</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Retinopathy of Prematurity
2016
Angiogenesis Inhibitors
Antibodies
Bevacizumab/*analysis
Bouhenni Rachida
Department of Pharmaceutical Sciences
Gestational Age
Hanna Nancy
Hertle Richard W
Humanized
Humans
Hypes Stephen
Infant
Intravitreal Injections
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
Lawhon William
Monoclonal
Nasser Orwa
NEOMED College of Pharmacy
Newborn
Vascular Endothelial Growth Factor A
Vitreous Body/*chemistry